GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoMed Pharmaceuticals Inc (NAS:OMED) » Definitions » Operating Margin %

OncoMed Pharmaceuticals (OncoMed Pharmaceuticals) Operating Margin % : -31.08% (As of Dec. 2018)


View and export this data going back to 2013. Start your Free Trial

What is OncoMed Pharmaceuticals Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. OncoMed Pharmaceuticals's Operating Income for the three months ended in Dec. 2018 was $-3.17 Mil. OncoMed Pharmaceuticals's Revenue for the three months ended in Dec. 2018 was $10.18 Mil. Therefore, OncoMed Pharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2018 was -31.08%.

The historical rank and industry rank for OncoMed Pharmaceuticals's Operating Margin % or its related term are showing as below:


OMED's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -169.17
* Ranked among companies with meaningful Operating Margin % only.

OncoMed Pharmaceuticals's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

OncoMed Pharmaceuticals's Operating Income for the three months ended in Dec. 2018 was $-3.17 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2018 was $-8.19 Mil.


OncoMed Pharmaceuticals Operating Margin % Historical Data

The historical data trend for OncoMed Pharmaceuticals's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoMed Pharmaceuticals Operating Margin % Chart

OncoMed Pharmaceuticals Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Operating Margin %
Get a 7-Day Free Trial Premium Member Only -127.97 -330.35 -411.03 -100.77 -18.45

OncoMed Pharmaceuticals Quarterly Data
Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.02 -75.58 -71.15 29.67 -31.08

Competitive Comparison of OncoMed Pharmaceuticals's Operating Margin %

For the Biotechnology subindustry, OncoMed Pharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoMed Pharmaceuticals's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoMed Pharmaceuticals's Operating Margin % distribution charts can be found below:

* The bar in red indicates where OncoMed Pharmaceuticals's Operating Margin % falls into.



OncoMed Pharmaceuticals Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

OncoMed Pharmaceuticals's Operating Margin % for the fiscal year that ended in Dec. 2018 is calculated as

Operating Margin %=Operating Income (A: Dec. 2018 ) / Revenue (A: Dec. 2018 )
=-8.194 / 44.421
=-18.45 %

OncoMed Pharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2018 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2018 ) / Revenue (Q: Dec. 2018 )
=-3.165 / 10.184
=-31.08 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OncoMed Pharmaceuticals  (NAS:OMED) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


OncoMed Pharmaceuticals Operating Margin % Related Terms

Thank you for viewing the detailed overview of OncoMed Pharmaceuticals's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoMed Pharmaceuticals (OncoMed Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
800 Chesapeake Drive, Redwood City, CA, USA, 94063
OncoMed Pharmaceuticals Inc is a clinical-stage biotechnology company. The aim of the company is to address cancer initiation, growth, metastases, and recurrence by developing alternative therapies to fight cancer. Its core therapy uses monoclonal antibodies targeting cancer stem cells. The company has strategic alliances with Celgene, Bayer Pharma, and GlaxoSmithKline.
Executives
Perry A Karsen director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Deepika Pakianathan director 160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402
Jack W Lasersohn director 18 BANK STREET, SUMMIT NJ 07901
Jonathan D Root director 2735 SAND HILL ROAD, MENLO PARK CA 94025
Michael S Wyzga director RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, CAMBRIDGE MA 02139
Rick E Winningham director 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Denise Scots-knight director C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02139
Sunil Patel officer: See Remarks 11085 NORTH TORREY PINES RD., SUITE 300, LA JOLLA CA 92037
Paul J Hastings officer: Chairman & CEO 61 HARTFORD STREET, SAN FRANCISCO CA 94114
Laurence Lasky director C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Jakob Dupont officer: SVP & Chief Medical Officer C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Terry P Gould director C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Usvp Entrepreneur Partners Viii A L P 10 percent owner P O BOX 7460, MENLO PARK CA 94026
Usvp Entrepreneur Partners Viii B L P 10 percent owner P O BOX 7460, MENLO PARK CA 94026
Usvp Viii Affiliates Fund L P 10 percent owner 2735 SAND HILL ROAD, MENLO PARK CA 94025

OncoMed Pharmaceuticals (OncoMed Pharmaceuticals) Headlines